NASDAQ:ADMP - Adamis Pharmaceuticals Stock Price, Forecast & News

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) announced its quarterly earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.06. The specialty pharmaceutical company earned $5.90 million during the quarter, compared to analysts' expectations of $6.55 million. Adamis Pharmaceuticals had a negative net margin of 175.77% and a negative return on equity of 90.00%. View Adamis Pharmaceuticals' Earnings History.

Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Adamis Pharmaceuticals.

4 Wall Street analysts have issued 12-month price targets for Adamis Pharmaceuticals' shares. Their forecasts range from $1.10 to $6.00. On average, they anticipate Adamis Pharmaceuticals' stock price to reach $3.70 in the next year. This suggests a possible upside of 506.3% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamis Pharmaceuticals.

Media headlines about ADMP stock have been trending very negative on Tuesday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Adamis Pharmaceuticals.

Some companies that are related to Adamis Pharmaceuticals include Marinus Pharmaceuticals (MRNS), Genprex (GNPX), Galectin Therapeutics (GALT), IDEAYA Biosciences (IDYA), PhaseBio Pharmaceuticals (PHAS), Sierra Oncology (SRRA), CELYAD SA/ADR (CYAD), Newron Pharmaceuticals (NWPHF), Aldeyra Therapeutics (ALDX), NeuBase Therapeutics (NBSE), ProMetic Life Sciences (PFSCF), Cassava Sciences (SAVA), Menlo Therapeutics (MNLO), Cyclerion Therapeutics (CYCN) and Aravive (ARAV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Trevena (TRVN), Verastem (VSTM), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Novavax (NVAX), Amarin (AMRN), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Adamis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (1.02%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert B Rothermel, Robert O Hopkins and Ronald B Moss. View Institutional Ownership Trends for Adamis Pharmaceuticals.

ADMP stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. View Insider Buying and Selling for Adamis Pharmaceuticals.

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMP stock can currently be purchased for approximately $0.61.

Adamis Pharmaceuticals has a market capitalization of $37.62 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe.View Additional Information About Adamis Pharmaceuticals.

The official website for Adamis Pharmaceuticals is http://www.adamispharmaceuticals.com/.

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]